Tokyo, Japan, June 1, 2006 - (JCN Newswire) - Astellas Pharma Inc. (TSE: 4503) today announced that Vesicare(R) (generic name: solifenacin succinate), indicated for the treatment of the overactive bladder (OAB), will be available in the Japanese market on June 8, 2006, following its drug price listing today at 119.70 yen per 2.5mg tablet and 201.60 yen per 5mg tablet.
